Nkarta (NASDAQ:NKTX) Releases Earnings Results

Nkarta (NASDAQ:NKTX) issued its earnings results on Wednesday. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06, Zacks reports.

Nkarta Price Performance

Nkarta stock opened at $1.97 on Friday. The stock has a market cap of $139.02 million, a price-to-earnings ratio of -1.05 and a beta of 0.90. The firm has a 50 day simple moving average of $2.00 and a 200-day simple moving average of $2.89. Nkarta has a 1-year low of $1.31 and a 1-year high of $11.84.

Insiders Place Their Bets

In other Nkarta news, CEO Paul J. Hastings sold 17,378 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total transaction of $38,231.60. Following the sale, the chief executive officer now directly owns 319,859 shares in the company, valued at approximately $703,689.80. The trade was a 5.15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 8.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on NKTX. Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of Nkarta in a research report on Thursday. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Nkarta in a report on Thursday. Finally, Stifel Nicolaus decreased their price objective on Nkarta from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $14.86.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.